

MEETING MINUTES

Consortium for Medical Marijuana Clinical Outcomes Research: BOARD MEETING (SPECIAL)

Friday, September 13, 2019 at 4:00pm

1225 Center Drive, HPNP 2309, Gainesville, FL 32610 or Remote Connection via Zoom

Board Members Present:

Roger Fillingim, Chair
Daniel Flynn, Vice Chair
Martha Rosenthal
Dalton Dietrich
Eric Holmes
Tim Gilbertson
Cynthis Hughes Harris
Max Orezzaoli

Attendees:

Almut Wintersein, Consortium Director
Bob Cook, Consortium Associate Director
Yan Wang
Juan Hincapie-Castillo
Amie Goodin
Sebastian Jugl
Golnoosh Alipour Haris
Bob Pellegrino

Opening Remarks

The Chair called the meeting to order at 4:00pm. He welcomed all new and returning Board Members and asked the new Board Member, Dr. Max Orezzaoli from Florida Memorial University, to introduce himself. The Chair asked all Board Members for disclosures of conflicts of interest before proceeding with new business. No Board Members had conflicts of interest to disclose.

Presentation of Proposed Grants Program Funding Opportunity Announcement

The Chair stated that no revisions or comments were submitted via email from Board Members following last week's distribution of draft materials. The Chair asked Dr. Winterstein and Dr. Cook to summarize the RFA draft document. Dr. Winterstein introduced each section of the RFA and explained that the Consortium has established an email address for contact (mmj.outcomes@cop.ufl.edu), which will receive and direct questions and will also receive grant application submissions. Vice Chair Flynn requested discussion regarding whether there should be limited submissions from Consortium member institutions. Several Board Members contributed to this discussion and it was agreed that no limits on number of submissions will be enacted for this RFA.

Board Members did not have further comments regarding the review criteria, award amounts, or application summary components of the RFA materials following presentation by Dr. Winterstein. Dr. Orezzaoli requested clarification regarding whether Board Members were eligible for grant submission as applicants. Following discussion, Board Members agreed that submissions as co-Investigators or consultants were permissible but that Board Members would recuse themselves from funding decisions where applicable. It was agreed that Board Members were not eligible to submit applications as Principal Investigators.

Dr. Dietrich requested explanation regarding if and how the Consortium were able to provide and/or manage marijuana products suitable for clinical trials in humans. Dr. Cook explained that at this time the Clinical Core could not directly provide marijuana products for human clinical trials, but that the Clinical Core is working to identify the scope of services that would be useful and available to Consortium members in the future.

Vote on Grants Program Funding Opportunity Announcement

The Chair requested further comment on the grants program funding opportunity announcement and asked whether there was a motion to proceed. Dr. Rosenthal made a motion to approve the RFA as written. The motion was seconded by Dr. Orezzaoli. The Chair called the vote and the motion to approve the RFA as written passed unanimously, and so the RFA will be released as presented.

Remaining Business

The Chair reminded Board Members that they need to distribute the RFA through their university communities quickly when they receive the finalized version Monday. The Chair requested feedback on preference for scheduling the grants review decision meeting in November in person or remotely by videoconference. Board Members agreed to attend remotely and Vice Chair Flynn requested that a Doodle poll be distributed to schedule this meeting during the week of November 18th, Monday through Thursday.

Public Comments

The Chair invited comments from the public and none were submitted.

Closing Remarks

The Chair stated that announcements and reminders about the next meeting will be delivered in the coming weeks. During the November meeting, the Board will assess grants program reviewer comments and decide which grants to fund.

Adjournment

The Chair adjourned the meeting at 5:00pm.